A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PATIENTS WITH GUILLAIN-BARRÉ SYND
Clinical Trial Grant
Administered By
Neurology, Neuromuscular Disease
Awarded By
Genetech
Start Date
September 30, 2022
End Date
October 25, 2023
Administered By
Neurology, Neuromuscular Disease
Awarded By
Genetech
Start Date
September 30, 2022
End Date
October 25, 2023